18508 Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Dermatology Unit, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
J Cutan Med Surg. 2023 Mar-Apr;27(2):126-132. doi: 10.1177/12034754231155889. Epub 2023 Feb 21.
IL-23 inhibitors are the latest class of biologic drugs approved for moderate-to-severe psoriasis.
to investigate real-life safety and efficacy of tildrakizumab.
demographic data, medical history, psoriasis disease history, PASI, DLQI, BSA, NAPSI were recorded at weeks 0, 12, 24, 36.
PASI, BSA, DLQI and NAPSI all decreased rapidly during the 36 week follow-up period. PASI score reduced from 12.28 to 4.65 by week 12, followed by a further decrease to 1.18 at week 36 Multiple logistic regression showed that smoking, BMI ≥30, ≥3 comorbidities, previous systemic traditional or biologic drugs, psoriatic arthritis nor difficult-to-treat areas influenced the reduction of PASI and NAPSI scores during treatment with tildrakizumab ( > .05).
we assessed a good performance of tildrakizumab in patients with multiple comorbidities, multi-failure, elderly patients, and in subjects with psoriatic arthritis.
白细胞介素-23 抑制剂是最近批准用于中度至重度银屑病的生物药物类别。
研究替西单抗的真实疗效和安全性。
在第 0、12、24、36 周记录人口统计学数据、病史、银屑病病史、PASI、DLQI、BSA、NAPSI。
在 36 周的随访期间，PASI、BSA、DLQI 和 NAPSI 均迅速下降。PASI 评分从第 12 周的 12.28 降至第 4.65，第 36 周进一步降至 1.18。多因素逻辑回归显示，吸烟、BMI≥30、≥3 种合并症、既往全身传统或生物药物治疗、银屑病关节炎或难治性区域不影响替西单抗治疗期间 PASI 和 NAPSI 评分的降低（>0.05）。
我们评估了替西单抗在患有多种合并症、多次失败、老年患者以及患有银屑病关节炎的患者中的良好疗效。
